Skip to content
GTx logo — Innovative and passionate experts providing advanced medicin...

GTx

Innovative and passionate experts providing advanced medicines through proven methods.

Founded 1997 Post-IPO Equity Total: $163.18M Biopharma, Biotechnology +1

General Information

Company Name GTx
Founded Year 1997
Founders / Decision Makers
Team member
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with GTx. To contact GTx, visit gtxinc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GTx compare?

A PDF of GTx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GTx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GTx

GTx is a biopharma and biotechnology startup that has been revolutionizing the health care industry since its establishment in 1997. With the slogan "Innovative and passionate experts providing advanced medicines through proven methods," GTx, Inc. is committed to delivering better medicines with new science through established pathways. The company recently received a significant $48.50M Post-IPO Equity investment on 26 September 2017, with notable investors including Abingworth, Aisling Capital, Boxer Capital, Amzak Health, and CAM Capital. This investment signifies strong support and confidence in GTx's innovative approach and groundbreaking solutions in the healthcare sector.

Business keywords: pharmaceuticals, medicine, innovation, medical research, drug development, science, advanced therapies, biomedical engineering

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $48.50M 5
Abingworth, Aisling Capital +3
26 Sep 2017
Post IPO Equity $43.41M 1
Biotechnology Value Fund
24 Nov 2014
Post IPO Equity $21.27M -
06 Mar 2014
Post IPO Equity $30.00M -
10 Jan 2008
Series E $20.00M 3
MB Venture Partners, Oracle +1
20 Aug 2003

GTx Alternatives & Competitors

View All Alternatives
GTx vs
Kayothera
Kayothera United States

Drugging the Undruggable with 1st-in-class RAR/RXR Nuclear Receptor Pathway Inhibitors. EFL Life Sci...

Series A
5 employees
Biotechnology, Health Care
GTx vs
Chimeron Bio
Chimeron Bio United States

Redefining genetic medicine with future-forward RNA technology designed to deliver meaningful patien...

Angel
12 employees
Biotechnology, Health Care
GTx vs
Second Genome Inc.
Second Genome Inc. United States

Discovering and developing transformational precision therapies.

Series B
6 employees
Biotechnology, Health Care

FAQ About GTx

Innovative and passionate experts providing advanced medicines through proven methods.
GTx was founded in 1997.
GTx operates in Biopharma, Biotechnology and Health Care. Its work centres on pharmaceuticals, medicine, innovation and medical research.
GTx has completed 5 funding rounds, raising a total of $163.18M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to GTx include Kayothera, Chimeron Bio, Second Genome Inc., Inoviv, SonoThera. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GTx and Kayothera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GTx, https://bouncewatch.com/company/gtx, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout